News Releases

January 19, 2024

Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

January 17, 2024

Apollomics to Participate in a Fireside Chat at the B. Riley Securities’ 2024 Virtual Oncology Conference

January 3, 2024

Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia

January 2, 2024

Apollomics to Present at the 2024 Biotech Showcase